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ABSTRACT Hereditary breast-ovarian cancer syndrome contributes to as much as 5–7% of breast cancer (BC) 
and 10–15% of ovarian cancer (OC) incidence. Mutations in the “canonical” genes BRCA1 and BRCA2 occur 
in 20–30% of affected pedigrees. In addition to BRCA1 and BRCA2 mutations, germ-line lesions in the CHEK2, 
NBS1, and PALB2 genes also contribute to familial BC clustering. The epidemiology of hereditary breast-ovarian 
cancer in Russia has some specific features. The impact of the “founder” effect is surprisingly remarkable: a sin-
gle mutation, BRCA1 5382insC, accounts for the vast majority of BRCA1 defects across the country. In addition, 
there are two other recurrent BRCA1 alleles: BRCA1 4153delA and BRCA1 185delAG. Besides BRCA1, in Russia 
breast cancer is often caused by germ-line alterations in the CHEK2 and NBS1 genes. In contrast to BRCA1 and 
BRCA2, the CHEK2 and NBS1 heterozygosity does not significantly increase the OC risk. Several Russian breast 
cancer clinics recently started to investigate the efficacy of cisplatin in the therapy of BRCA1-related cancers; 
initial results show a unique sensitivity of BRCA1-associated tumours to this compound.
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INTRODUCTION
Breast cancer (BC) and ovarian cancer (OC) contrib-
ute significantly to cancer incidence and mortality. BC 
is the most frequent malignant pathology in women, 
with the lifetime risk reaching approximately 10%. In 
some cases, BC can be easily diagnosed at early stages 
and ultimately cured. Unfortunately, even with the 
implementation of total population screening, the BC 
related mortality rate has not decreased significantly, 
due to insufficient sensitivity of available diagnostic 
methods, as well as the high metastatic potential of 
some BC forms [1]. OC is a much rarer disease than BC, 
being found only in 1.5% of women around the world; 
however, it is almost always diagnosed at late (incur-
able) stages. Early ovarian tumours do not cause  symp-
toms and are often missed by ultrasound examination 
and  СА-125 biomarker assay [2]. Both BC and OC are 
diseases of the reproductive system; therefore, their 
hormonal, metabolic, and behavioural risk factors are 
common to a certain extent. Interestingly, these two 
diseases are the main components of the most frequent 
genetic disease – hereditary breast-ovarian cancer 
(HBOC) syndrome [3].
HBOC has been intensively studied since the early 
1990s. In 1994, the first gene associated with this syn-
drome was discovered and named  BRCA1 (BReast 
CAncer 1) [4], and the second gene, BRCA2, was dis-
covered a year later [5]. Although BRCA1 and BRCA2 
code for different proteins, their products play a key 
role in preserving genome integrity by participating in 
DNA repair [6]. Notably, BRCA1 or BRCA2 mutations 
occur only in 20–30% of familial BC/OC cases. There 
has been an active search for other hereditary BC/OC 
genes. The effort has already helped to identify several 
new relevant genes, e.g. CHEK2, NBS1, PALB2 etc. [7].
The first studies on the contribution of the BRCA1 
and BRCA2 genes in BC and OC incidence were per-
formed on European and North American women. The 
mutations in these genes are very diverse [8], which 
complicates BRCA diagnostics. Indeed, to perform the 
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complete analysis of BRCA1 and BRCA2, one needs not 
only to perform full sequencing of these long genes, but 
also to find rearrangements using the MPLA method 
(multiplex ligation-dependent probe amplification). 
In the mid-1990s, it was established that the so-called 
“founder effect” was present in some small isolated 
ethnic groups. For example, in females Ashkenazi Jew 
nearly all BRCA1 and BRCA2 mutations are represent-
ed by only 3 recurrent alleles, i.e. BRCA1 185delAG, 
BRCA1 5382insC, BRCA2 6174delT; BRCA2 999del5 is 
a prevailing mutation in Icelandic females [9, 10]. Pop-
ulation-specific distribution of hereditary cancer mu-
tations may  significantly affect the design of genetic 
studies. In countries without a strong founder effect, 
only cancer cases with a high probability of detecting 
the mutation are usually taken into the analysis; they 
include oncological patients with a proven cancer his-
tory in their family and/or patients with multiple pri-
mary tumours and/or young women with BC or OC. 
The presence of the founder effect greatly simplifies 
the DNA testing procedure, enabling comprehensive 
studies, such as revealing the influence of hereditary 
cancer gene mutations on the overall BC/OC incidence 
rate, as well as analyzing the gene mutations in healthy 
women [11].
EPIDEMIOLOGY OF THE BRCA1, BRCA2, 
CHEK2 AND NBS1 MUTATIONS IN RUSSIA
In Russia, the studies of the HBOC syndrome were 
initiated later than in the U.S. and Europe but they 
produced rather unexpected results. The first paper 
published in 1997 reported on the results obtained in 
patients with familial OC living in Moscow and sev-
eral other regions of the former Soviet Union [12], the 
main result being the extremely high frequency of the 
BRCA1 5382insC mutation. As was mentioned above, 
this mutation had been first found in Jewish women; 
therefore, it had been for many years considered in the 
context of that particular ethnic group [13]. However, 
it appeared that the BRCA1 5382insC mutation was 
not of Jewish origin. This mutation is found not only 
in females living in various regions of Russia, but also 
in native populations of Poland, Lithuania, Latvia, and 
Belarus [14–17]. It is perhaps more accurate to say that 
the BRCA1 5382insC mutation is of Slavic origin, and 
that the relatively high frequency of this mutation in 
Ashkenazi Jews observed mostly in Eastern Europe 
is likely due to the long coexistence of the Slavic and 
Jewish peoples in the Baltic region and adjacent ter-
ritories.
The epidemiology of the BRCA1 5382insC mutation 
is surprising, to say the least, since it contradicts the 
stereotype of the multinational culture in the Russian 
Empire and the Soviet Union.  BRCA1 5382insC ac-
counts for up to 90% of all BRCA1 mutations in women 
living in distant regions of Russia, ranging from Mos-
cow to St. Petersburg, Krasnodar, Tomsk, etc. [12, 18–
20, 22–24, 26]. Moreover, this mutation is dominant in 
neighboring countries with a mostly Slavic population 
such as Poland, Belarus, Latvia, and Lithuania [14–17]. 
Notably, the relative genetic homogeneity of the Slavs 
is in accordance with the results of general popula-
tion studies on the genetic diversity of people living in 
Russia [31]. The BRCA1 5382insC allele frequency in 
healthy women is approximately 0.1%. This variant ac-
counts for approximately 2–5% of  total BC cancer inci-
dence. Among the high-risk patients (familial cancers, 
bilateral breast tumours, or early onset cancers), this 
mutation is observed in 10% of patients. The BRCA1 
5382insC contribution to the OC rate is even bigger: 
this mutation is found in 10–15% of patients (Table). 
It is important to note that in contrast to the BC, the 
BRCA1 5382insC distribution in women with OC is in-
dependent of age, family history, and the number of 
primary tumours [26]. Therefore, while DNA testing of 
BC patients can be restricted by high-risk cases, all OC 
patients have to undergo BRCA testing. 
In the pioneering report [12], the relatively frequent 
BRCA1 4153delA (4154delA) mutation was described. 
The mutation was found not only in Russian patients, 
but also in those from other neighboring Slavic coun-
tries [14–17]. The BRCA1 4153delA frequency in Rus-
sian patients, however, is an order of magnitude lower 
than that of the  BRCA1 5382insC mutation, which 
complicates the study of the BRCA1 4153delA epide-
miology. Polish scientists had reported on the prefer-
ential association of BRCA1 4153delA with OC [14, 32]; 
however, their observations could not be confirmed in 
later studies [21].
A number of Russian studies indicate that there is 
a relatively high frequency of the “Jewish”  BRCA1 
185delAG allele in Russian patients [20, 23, 24, 26]. In 
contrast to the BRCA1 5382insC mutation, however, 
this mutation is not dominant and could be better ex-
plained by interethnic marriages.
The BRCA1 gene mutations in familial BC/OC pa-
tients have been repeatedly analyzed by sequencing of 
all coding sections, with similar results obtained in Mos-
cow, St. Petersburg, and Tomsk. It has been shown that 
non-founder mutations are much rarer in Russia than 
in Europe and North America [12, 18–20, 23, 33]. Given 
the rapidly falling costs of DNA analysis, it is logical 
to expect an increase in the use of BRCA1 sequencing 
even for the patients with low probability of cancer 
genetic predisposition. So far, there has been only one 
study on gross rearrangements of the BRCA1 gene, and 
the data indicate a low frequency of such mutations in 
Russian patients with hereditary BC/OC [33].REVIEWS
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While the BRCA1 gene has been systematically 
analyzed, data on the BRCA2 mutations in Russia are 
scarce. In Siberia, there have been several reported 
cases of BRCA2 being inactivated in hereditary BC/
OC patients [18]; at the same time, studies performed 
in Moscow revealed no connection between this gene 
and hereditary BC/OR in the European part of Russia 
[23]. Polish scientists performed comprehensive studies 
showing that the BRCA2 mutations contributed very 
little to BC and OC aetiology in Slavs [34].
Another interesting feature of Russian patients is the 
frequent occurrence of CHEK2 mutations. This gene, 
as  BRCA1 and BRCA2, participates in the maintain-
ing of genomic integrity. Heterozygous CHEK2 muta-
tions are frequent in Finland, the Netherlands, Poland, 
and several other countries [14, 35]. In Russia, CHEK2 
mutations are found in fewer than 2% of “random” 
BC patients, and in up to 5% of hereditary cancer pa-
tients [27]. In contrast to the situation with BRCA1 and 
BRCA2, heterozygous inactivation of CHEK2 does not 
increase the risk of OC [21, 26].
Another important gene for Russia is NBS1 (NBN). 
Homozygous defects of this gene were found in pa-
tients with serious immunodeficiency, the so-called Ni-
jmegen breakage syndrome [36]. Heterozygous NBS1 
mutations are observed mostly in Slavs, and they are 
associated with an increased BC risk [30, 37, 38]. No in-
creased frequency of this gene defect is observed in OC 
patients [26]. Nevertheless, in the only reported case 
of combined germ-line heterozygosity for BRCA1 and 
NBS1 genes in ovarian tumor, there was somatic inac-
tivation of the NBS1 gene, whereas the BRCA1 gene 
remained intact [39]. This observation may be an argu-
ment speaking in favor of the involvement of the NBS1 
gene in the degree of OC risk.
MEDICAL ASPECTS OF HEREDITARY 
BC AND OC IN RUSSIA
The main goal of hereditary cancer syndrome diagnostics 
is to find healthy women with corresponding mutations. 
It is believed that timely detection of the genetic defect 
can help to avoid fatal cancer outcome. Women with het-
erozygous BRCA1 and BRCA2 genes are under regular 
observation for early BC/OC diagnostics. In addition, 
preventive surgical removal of target tissues is recom-
mended [40] to women with a BRC A mutation [40].
Healthy carriers of hereditary cancer genes are usu-
ally found during the examination of relatives of BC 
or OC patients with the genetic defect. According to 
current ethical standards, the patient herself should 
encourage her relatives to undergo DNA analysis. Our 
experience shows that very few relatives of the BRCA 
mutation carriers undergo DNA testing. This could be 
because either hereditary cancer patients conceal their 
condition to their relatives or the healthy women avoid 
medical procedures aimed at determining cancer risk. 
Even more surprising is the fact that the majority of 
healthy women with BRCA1 mutations monitored by 
us are extremely careless when it comes to undergoing 
preventive screening. Preventive surgery presents the 
biggest challenge. While it has become a routine clinical 
practice in the U.S., Canada, Western and Eastern Eu-
rope, Israel, Australia, South Africa, Japan, Korea and 
other countries, yet in Russia the discussion of such an 
option is suppressed or distorted not only by ordinary 
people but even by the medical community.
While preventive measures for BRCA carriers are 
frequently neglected, many doctors are enthusiastic to 
try novel therapeutic schemes for HBOC patients. In 
2009, Polish scientists published the results of clinical 
studies showing the unique sensitivity of BRCA1-asso-
ciated tumors to cisplatin [41]. This is possible because 
of unique therapeutic window. In tumors of the BRCA1 
mutation carriers, complete inactivation of this gene 
is observed. It causes a homologous recombination de-
fect. BRCA1-deficient cells are extremely vulnerable 
to cisplatin, a well-known DNA crosslinking compound 
causing double-strand breaks. It is important that nor-
mal tissues, in contrast to neoplasms, retain hetero-
zygous BRCA1 status, the presence of a single func-
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BRCA1 5382insC, 4153delA, 185delAG ~ 0.1% ~ 10% 2–4% > 10% [18–26]
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tional copy of the gene being sufficient for performing 
its functions. Russian scientists were the first to provide 
independent confirmation of the results of Byrski et al. 
[42]. Cisplatin is now commonly used for the therapy of 
BRCA1-associated tumors in several Russian clinics.
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